Trials / Completed
CompletedNCT03430895
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Metastatic, Non-transitional Cell Carcinoma of the Urothelial Tract
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done test to test the safety and effectiveness of durvalumab combined with tremelimumab in patients who have a rare form of cancer of the urinary tract.
Conditions
- Non-Transitional Cell Carcinoma of the Urothelial Tract
- Small Cell of the Bladder
- Adenocarcinoma of the Bladder
- Squamous Cell Carcinoma of the Bladder
- Metastatic Bladder Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | durvalumab and tremelimumab | Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting 4 weeks after the last combination treatment for up to 9 doses. |
Timeline
- Start date
- 2018-01-31
- Primary completion
- 2021-02-10
- Completion
- 2021-02-10
- First posted
- 2018-02-13
- Last updated
- 2021-12-01
- Results posted
- 2021-12-01
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03430895. Inclusion in this directory is not an endorsement.